MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Genetic Determinants of the Response to Salbutamol Among Asthma Patients

Not Applicable
Conditions
Asthma
First Posted Date
2005-09-13
Last Posted Date
2008-10-29
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
150
Registration Number
NCT00162396
Locations
🇮🇱

Hadassah Medical Organization, Jerusalem, Israel

Genetic Determinants of the Bronchodilatation Effect of Albuterol ex-Vivo

Not Applicable
Conditions
Asthma
First Posted Date
2005-09-13
Last Posted Date
2008-10-29
Lead Sponsor
Hadassah Medical Organization
Target Recruit Count
150
Registration Number
NCT00162422
Locations
🇮🇱

Hadassah Medical Organization, Jerusalem, Israel

Treatment of Multiple Sclerosis With Copaxone and Albuterol

Not Applicable
Completed
Conditions
Autoimmune Diseases
Multiple Sclerosis
Interventions
First Posted Date
2002-06-20
Last Posted Date
2016-09-22
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
40
Registration Number
NCT00039988
Locations
🇺🇸

Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts, United States

Study of Albuterol and Oxandrolone in Patients With Facioscapulohumeral Dystrophy (FSHD)

Not Applicable
Completed
Conditions
Muscular Dystrophies
First Posted Date
2001-12-07
Last Posted Date
2015-03-25
Lead Sponsor
FDA Office of Orphan Products Development
Target Recruit Count
160
Registration Number
NCT00027391
Locations
🇺🇸

Ohio State University Medical Center, Columbus, Ohio, United States

A Multi-Centered Study of the Long-Term Effect of Salmeterol and Albuterol in Cystic Fibrosis

Not Applicable
Suspended
Conditions
Cystic Fibrosis
First Posted Date
2000-04-14
Last Posted Date
2005-06-24
Lead Sponsor
National Center for Research Resources (NCRR)
Registration Number
NCT00005110
Locations
🇺🇸

Division of Allergy and Pulmonary Medicine, St. Louis, Missouri, United States

Randomized Study of Albuterol in Patients With Facioscapulohumeral Muscular Dystrophy

Not Applicable
Completed
Conditions
Muscular Dystrophy, Facioscapulohumeral
First Posted Date
2000-02-25
Last Posted Date
2015-03-25
Lead Sponsor
Ohio State University
Target Recruit Count
90
Registration Number
NCT00004685

Asthma Clinical Research Network (ACRN)

Phase 3
Withdrawn
Conditions
Lung Diseases
Asthma
First Posted Date
1999-10-28
Last Posted Date
2017-01-16
Lead Sponsor
Milton S. Hershey Medical Center
Registration Number
NCT00000577
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

University of California, San Francisco, San Francisco, California, United States

🇺🇸

University of California at San Diego, La Jolla, California, United States

and more 4 locations
© Copyright 2025. All Rights Reserved by MedPath